curacle co.,ltd. (KOSDAQ:365270)

Market Cap	63.95B
Revenue (ttm)	1.13B
Net Income (ttm)	-18.69B
Shares Out	14.01M
EPS (ttm)	-1,343.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	819,028
Average Volume	378,911
Open	5,640.00
Previous Close	5,770.00
Day's Range	4,870.00 - 5,800.00
52-Week Range	3,600.00 - 9,100.00
Beta	1.74
RSI	41.25
Earnings Date	n/a

About curacle co.,ltd.

Curacle Co., Ltd., a bio-venture business, engages in the research and development of drugs for diseases caused by aging process and damage to blood vessels. Its products cover age-related vascular diseases, intractable metabolic diseases, and cancer targeting/immunotherapy. The company’s products in pipeline include CU06, which covers treatment and medical indications, such as diabetic macular edema/retinopathy, acute respiratory distress syndrome, myocardial infarction, stroke treatment, concomitantly used with immunotherapy, inflammatory bow...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2016
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 365270

Financial Performance

In 2024, curacle co.,ltd.'s revenue was 1.63 billion, a decrease of -84.14% compared to the previous year's 10.29 billion. Losses were -14.89 billion, 28.5% more than in 2023.